International journal of transgender health · 2025
Aggression changes during masculinizing and feminizing gender-affirming hormone therapy (GAHT) - A prospective clinical study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taulbjerg Kristensen Tine, Lehmann Christensen Louise, Skov Ole, Viola Buskbjerg Palm Camilla, T'Sjoen Guy, Skovsager Andersen Marianne, Glintborg Dorte, Roessler Kirsten K
Аннотация
INTRODUCTION: Testosterone and aggression have been positively associated, but it remains unclear whether gender-affirming hormone therapy (GAHT)-induced testosterone changes affect aggression in transgender persons. This study investigates aggression changes and associations between aggression and testosterone, depression, and anxiety during the first year of GAHT.
METHODS: Alternative-Short-Aggression-Questionnaire scores were assessed in transmasculine and transfeminine adults at baseline, six weeks, and one year post-GAHT initiation. Cisgender men and women were the comparison groups. Linear mixed effect models evaluated aggression score changes and group-differences, including effects of testosterone, depression, and anxiety, controlling for age and education.
RESULTS: Baseline data included 50 transmasculine (median age = 22 years), 62 transfeminine (median age = 24 years), 176 cisgender men (median age = 31 years), and 470 cisgender women (median age = 25 years). Seventy-one percent of transgender participants completed all follow-ups. Total and verbal aggression scores decreased after one year across transmasculine and transfeminine persons (mean difference (MD) = -1.6, p = .018 and MD = -0.8, p = .004), with no changes in other aggression dimensions. At baseline, transmasculine participants showed higher total aggression (MD = 3.4, p = .009) and anger (MD = 1.8, p < .001) scores than transfeminine persons. Transmasculine (MD = 3.3, p = .015) and transfeminine (MD = 6.5, p = <.001) persons had lower total aggression scores than cisgender men. Testosterone was not associated with aggression, whereas anxiety was significantly positively associated with aggression scores.
DISCUSSION: There was no GAHT-induced increased aggression in transmasculine persons. Total aggression scores decreased after one year across GAHT-types. Transgender aggression scores were significantly lower than cisgender men, indicating no risk of pathological aggression in the transgender population. Limitations included participant numbers and self-report measures.
METHODS: Alternative-Short-Aggression-Questionnaire scores were assessed in transmasculine and transfeminine adults at baseline, six weeks, and one year post-GAHT initiation. Cisgender men and women were the comparison groups. Linear mixed effect models evaluated aggression score changes and group-differences, including effects of testosterone, depression, and anxiety, controlling for age and education.
RESULTS: Baseline data included 50 transmasculine (median age = 22 years), 62 transfeminine (median age = 24 years), 176 cisgender men (median age = 31 years), and 470 cisgender women (median age = 25 years). Seventy-one percent of transgender participants completed all follow-ups. Total and verbal aggression scores decreased after one year across transmasculine and transfeminine persons (mean difference (MD) = -1.6, p = .018 and MD = -0.8, p = .004), with no changes in other aggression dimensions. At baseline, transmasculine participants showed higher total aggression (MD = 3.4, p = .009) and anger (MD = 1.8, p < .001) scores than transfeminine persons. Transmasculine (MD = 3.3, p = .015) and transfeminine (MD = 6.5, p = <.001) persons had lower total aggression scores than cisgender men. Testosterone was not associated with aggression, whereas anxiety was significantly positively associated with aggression scores.
DISCUSSION: There was no GAHT-induced increased aggression in transmasculine persons. Total aggression scores decreased after one year across GAHT-types. Transgender aggression scores were significantly lower than cisgender men, indicating no risk of pathological aggression in the transgender population. Limitations included participant numbers and self-report measures.